PASADENA, Calif.–(BUSINESS WIRE)–Feb. 28, 2023– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA...
Comprehensive technical and safety review of large-scale medical isotope production facility complete JANESVILLE, Wisconsin, Feb. 27, 2023 – SHINE Technologies, LLC, a next-generation fusion technology company, today announced that the U.S. Nuclear Regulatory...
Associate scientist Jue Zhang and Morgridge affiliate Matthew Brown. Macrophages are specialized immune cells that can be adapted for the treatment of certain solid tumors by arming them with chimeric antigen receptors (CARs). Tumor-associated macrophages make up...
Greg Piefer, founder and CEO of SHINE Technologies, is interviewed by Mark Richardson, president of Unfinished Business Consulting, during the Cap Times Executive Breakfast at The Edgewater Hotel in Madison on Thursday, Feb. 16, 2023 Nuclear fusion may one day solve...
Accuray Incorporated (NASDAQ: ARAY) announced today that data from the randomized, multicenter trial PACE-A (PACE – Prostate Advances in Comparative Evidence) indicates that stereotactic body radiation therapy (SBRT), in comparison to surgery, better...
